open access

Vol 71, No 6 (2020)
Original paper
Published online: 2020-10-28
Submitted: 2020-04-29
Accepted: 2020-10-07
Get Citation

Comparison of serum adiponectin and osteopontin levels along with metabolic risk factors between obese and lean women with and without PCOS

Suleyman Erkan Alatas, Sevilay Yavuz Dogu, Derya Kilic, Tolga Guler
DOI: 10.5603/EP.a2020.0074
·
Pubmed: 33125692
·
Endokrynologia Polska 2020;71(6):497-503.

open access

Vol 71, No 6 (2020)
Original Paper
Published online: 2020-10-28
Submitted: 2020-04-29
Accepted: 2020-10-07

Abstract

Introduction: The objective of this study was to investigate the possible relation between serum adiponectin and osteopontin levels as metabolic risk markers among women with different polycystic ovary syndrome (PCOS) phenotypes.

Material and methods: In a University Hospital setting PCOS patients diagnosed according to Rotterdam Consensus Conference criteria with body mass index (BMI) between 18 and 35 were recruited.

Results: Overall, 57 PCOS patients and 57 age- and BMI-matched healthy controls were included in the study. Luteinising hormone (LH) to follicle-stimulating hormone FSH ratio (LH/FSH), free androgen index (FAI), and dehydroepiandrosterone sulphate (DHEAS-S) was found to be significantly higher in women with PCOS. There was significant interaction between PCOS status and obesity for serum adiponectin levels. Although mean adiponectin and osteopontin levels were similar among cases and controls, a further two-way ANOVA comparison within lean and obese subgroups revealed adiponectin to be significantly lower in lean PCOS women than in lean controls. LH/FSH ratio and adiponectin levels were all found to differ between lean counterparts; however, they did not show any correlation with metabolic markers [cholesterol, homeostatic model assessment (HOMA) or C-reactive protein (CRP) levels] in overall lean women or in the lean PCOS subgroup.

Conclusion: Serum adiponectin levels in lean PCOS women were significantly lower than those in lean controls. On the other hand, mean adiponectin and osteopontin levels were similar in PCOS cases and controls overall.

Abstract

Introduction: The objective of this study was to investigate the possible relation between serum adiponectin and osteopontin levels as metabolic risk markers among women with different polycystic ovary syndrome (PCOS) phenotypes.

Material and methods: In a University Hospital setting PCOS patients diagnosed according to Rotterdam Consensus Conference criteria with body mass index (BMI) between 18 and 35 were recruited.

Results: Overall, 57 PCOS patients and 57 age- and BMI-matched healthy controls were included in the study. Luteinising hormone (LH) to follicle-stimulating hormone FSH ratio (LH/FSH), free androgen index (FAI), and dehydroepiandrosterone sulphate (DHEAS-S) was found to be significantly higher in women with PCOS. There was significant interaction between PCOS status and obesity for serum adiponectin levels. Although mean adiponectin and osteopontin levels were similar among cases and controls, a further two-way ANOVA comparison within lean and obese subgroups revealed adiponectin to be significantly lower in lean PCOS women than in lean controls. LH/FSH ratio and adiponectin levels were all found to differ between lean counterparts; however, they did not show any correlation with metabolic markers [cholesterol, homeostatic model assessment (HOMA) or C-reactive protein (CRP) levels] in overall lean women or in the lean PCOS subgroup.

Conclusion: Serum adiponectin levels in lean PCOS women were significantly lower than those in lean controls. On the other hand, mean adiponectin and osteopontin levels were similar in PCOS cases and controls overall.

Get Citation

Keywords

 adiponectin; osteopontin; polycystic ovary syndrome

About this article
Title

Comparison of serum adiponectin and osteopontin levels along with metabolic risk factors between obese and lean women with and without PCOS

Journal

Endokrynologia Polska

Issue

Vol 71, No 6 (2020)

Article type

Original paper

Pages

497-503

Published online

2020-10-28

DOI

10.5603/EP.a2020.0074

Pubmed

33125692

Bibliographic record

Endokrynologia Polska 2020;71(6):497-503.

Keywords

 adiponectin
osteopontin
polycystic ovary syndrome

Authors

Suleyman Erkan Alatas
Sevilay Yavuz Dogu
Derya Kilic
Tolga Guler

References (30)
  1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19(1): 41–47.
  2. March WA, Moore VM, Willson KJ, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010; 25(2): 544–551.
  3. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012; 33(6): 981–1030.
  4. Liu S, Hu W, He Y, et al. Serum Fetuin-A levels are increased and associated with insulin resistance in women with polycystic ovary syndrome. BMC Endocr Disord. 2020; 20(1): 67.
  5. Yilmaz Ö, Temur M, Calan M, et al. The relationship between lipocalin-2 and free testosterone levels in polycystic ovary syndrome. Endokrynol Pol. 2017; 68(1): 7–12.
  6. Kuliczkowska-Płaksej J, Mierzwicka A, Jończyk M, et al. Preptin in women with polycystic ovary syndrome. Gynecol Endocrinol. 2018; 34(6): 470–475.
  7. Bostancı MS, Akdemir N, Cinemre B, et al. Serum irisin levels in patients with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 2015; 19(23): 4462–4468.
  8. Lim SS, Davies MJ, Norman RJ, et al. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012; 18(6): 618–637.
  9. Spritzer PM, Lecke SB, Satler F, et al. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction. 2015; 149(5): R219–R227.
  10. Rimmer M, Tan BK, Teede H, et al. Metabolic inflexibility in women with polycystic ovary syndrome: a systematic review. Gynecol Endocrinol. 2020; 36(6): 501–507.
  11. Mehta NN, McGillicuddy FC, Anderson PD, et al. Experimental endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes. 2010; 59(1): 172–181.
  12. Rolland YM, Haren MT, Patrick P, et al. Adiponectin levels in obese and non-obese middle-aged African-American women. Obes Res Clin Pract. 2007; 1(1): 1–78.
  13. Yadav A, Kataria MA, Saini V, et al. Role of leptin and adiponectin in insulin resistance. Clin Chim Acta. 2013; 417: 80–84.
  14. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007; 380(1-2): 24–30.
  15. Toulis KA, Goulis DG, Farmakiotis D, et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update. 2009; 15(3): 297–307.
  16. Singh A, Bora P, Krishna A. Direct action of adiponectin ameliorates increased androgen synthesis and reduces insulin receptor expression in the polycystic ovary. Biochem Biophys Res Commun. 2017; 488(3): 509–515.
  17. Ożegowska K, Bartkowiak-Wieczorek J, Bogacz A, et al. Relationship between adipocytokines and angiotensin converting enzyme gene insertion/deletion polymorphism in lean women with and without polycystic ovary syndrome. Gynecol Endocrinol. 2020; 36(6): 496–500.
  18. Baldani DP, Skrgatic L, Kasum M, et al. Altered leptin, adiponectin, resistin and ghrelin secretion may represent an intrinsic polycystic ovary syndrome abnormality. Gynecol Endocrinol. 2019; 35(5): 401–405.
  19. Saklamaz A, Calan M, Yilmaz O, et al. Polycystic ovary syndrome is associated with increased osteopontin levels. Eur J Endocrinol. 2016; 174(4): 415–423.
  20. Kuwabara Y, Katayama A, Tomiyama R, et al. Gonadotropin regulation and role of ovarian osteopontin in the periovulatory period. J Endocrinol. 2015; 224(1): 49–59.
  21. Wang Y, Zhou W, Wu C, et al. Circulating osteopontin and its association with liver fat content in non-obese women with polycystic ovary syndrome: a case control study. Reprod Biol Endocrinol. 2018; 16(1): 31.
  22. Ożga K, Krzyczkowska-Sendrakowska M, Hubalewska-Dydejczyk A, et al. The value of the free androgen index depends on the phenotype of polycystic ovary syndrome - a single-centre experience. Endokrynol Pol. 2019; 70(4): 330–335.
  23. Lim SS, Davies MJ, Norman RJ, et al. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012; 18(6): 618–637.
  24. Daan NMP, Koster MPH, de Wilde MA, et al. Biomarker Profiles in Women with PCOS and PCOS Offspring; A Pilot Study. PLoS One. 2016; 11(11): e0165033.
  25. Polak K, Czyzyk A, Simoncini T, et al. New markers of insulin resistance in polycystic ovary syndrome. J Endocrinol Invest. 2016; 40(1): 1–8.
  26. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, et al. Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Hum Reprod. 2006; 21(9): 2257–2265.
  27. Sieminska L, Marek B, Kos-Kudla B, et al. Serum adiponectin in women with polycystic ovarian syndrome and its relation to clinical, metabolic and endocrine parameters. J Endocrinol Invest. 2004; 27(6): 528–534.
  28. Behboudi-Gandevani S, Ramezani Tehrani F, Bidhendi Yarandi R, et al. The association between polycystic ovary syndrome, obesity, and the serum concentration of adipokines. J Endocrinol Invest. 2017; 40(8): 859–866.
  29. Kiefer FW, Zeyda M, Todoric J, et al. Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. Endocrinology. 2008; 149(3): 1350–1357.
  30. Nomiyama T, Perez-Tilve D, Ogawa D, et al. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest. 2007; 117(10): 2877–2888.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl